- 全部删除
- 您的购物车当前为空
Tifcemalimab(JS004)是一种靶向BTLA(B and T lymphocyte attenuator)的人源化抗体,可结合BTLA并阻断HVEM-BTLA的相互作用,具有免疫调节和抗肿瘤活性。
为众多的药物研发团队赋能,
让新药发现更简单!
Tifcemalimab(JS004)是一种靶向BTLA(B and T lymphocyte attenuator)的人源化抗体,可结合BTLA并阻断HVEM-BTLA的相互作用,具有免疫调节和抗肿瘤活性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 2,480 | In stock | |
5 mg | ¥ 6,470 | In stock | |
10 mg | ¥ 8,720 | In stock | |
25 mg | ¥ 12,900 | In stock | |
50 mg | ¥ 17,300 | In stock |
Tifcemalimab 相关产品
产品描述 | Tifcemalimab (JS004) is a humanised antibody targeting BTLA (B and T lymphocyte attenuator), which binds to BTLA and blocks the interaction between HVEM and BTLA, exhibiting immunomodulatory and antitumour activity. |
别名 | 替西利单抗, JS004 |
CAS No. | 2236068-83-8 |
颜色 | Transparent |
物理性状 | Liquid |
存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容